Has FDA Seen Your Facebook Yet?Has FDA Seen Your Facebook Yet?

The agency recently went after a pharmaceutical company for using the Facebook Share function, which could be the first time FDA has warned a company for Facebook promotion. The problem? FDA says that use of the button—at least where the drug Tasigna is concerned—is incomplete and misleading.

"The shared content is misleading because it makes representations about the efficacy of Tasigna but fails to communicate any risk information associated with the use of this drug," the FDA letter says, signed by Karen Rulli from FDA's Division of Drug Marketing, Advertising, and Communications. "In addition, the shared content inadequately communicates Tasigna's FDA-approved indication and implies superiority over other products."

Definitely something to keep in mind for medical device OEMs as they try to find ways to harness the power of social networking tools.